Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by Pfizer Inc.

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age

January 25, 2022

From Pfizer Inc.

Via Business Wire

Pfizer and OPKO Provide Update on the Biologics License Application for Somatrogon for Pediatric Growth Hormone Deficiency

January 21, 2022

From Pfizer Inc.

Via Business Wire

U.S. FDA Approves Pfizer’s CIBINQO® (abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitis

January 14, 2022

From Pfizer Inc.

Via Business Wire

Positive Top-Line Results of Pfizer’s Phase 3 Study Exploring Coadministration of PREVNAR 20™ With Pfizer-BioNTech COVID-19 Vaccine in Older Adults Released

January 12, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics

January 10, 2022

From Pfizer Inc.

Via Business Wire

Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases

January 10, 2022

From Pfizer Inc.

Via Business Wire

Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine

January 05, 2022

From Pfizer Inc.

Via Business Wire

Pfizer to Provide U.S. Government with an Additional 10 Million Treatment Courses of its Oral Therapy to Help Combat COVID-19

January 04, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

January 04, 2022

From Pfizer Inc.

Via Business Wire

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 12 Years of Age and Older

January 03, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

December 30, 2021

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to View and Listen to Webcast of February 8 Conference Call with Analysts

December 28, 2021

From Pfizer Inc.

Via Business Wire

Pfizer Receives U.S. FDA Emergency Use Authorization for Novel COVID-19 Oral Antiviral Treatment

December 22, 2021

From Pfizer Inc.

Via Business Wire

Pfizer to Provide the United Kingdom an Additional 2.5 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19

December 22, 2021

From Pfizer Inc.

Via Business Wire

Pfizer’s VYNDAQEL®/VYNDAMAX® Reduced the Risk of All-Cause Mortality by 41% Among Patients with Transthyretin Amyloid Cardiomyopathy, Five-Year Follow-Up Data Demonstrate

December 20, 2021

From Pfizer Inc.

Via Business Wire

Pfizer and BioNTech to Provide European Union More Than 200 Million Additional Doses of COMIRNATY® to Help Meet Continued Need for Vaccine Supply

December 20, 2021

From Pfizer Inc.

Via Business Wire

EMA Issues Advice for Potential Early Use of Pfizer’s Novel COVID-19 Oral Antiviral Candidate

December 16, 2021

From Pfizer Inc.

Via Business Wire

U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Ankylosing Spondylitis

December 14, 2021

From Pfizer Inc.

Via Business Wire

Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death

December 14, 2021

From Pfizer Inc.

Via Business Wire

Pfizer to Acquire Arena Pharmaceuticals

December 13, 2021

From Pfizer Inc.

Via Business Wire

Pfizer Declares First-Quarter 2022 Dividend

December 10, 2021

From Pfizer Inc.

Via Business Wire

European Commission Approves Pfizer’s Cibinqo® (abrocitinib) for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis

December 10, 2021

From Pfizer Inc.

Via Business Wire

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 16 Years and Older

December 09, 2021

From Pfizer Inc.

Via Business Wire

Pfizer and BioNTech Provide Update on Omicron Variant

December 08, 2021

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to Register for Webcast of Analyst and Investor Call to Discuss Pfizer-BioNTech COVID-19 Vaccine and Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate

December 07, 2021

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

November 24, 2021

From Pfizer Inc.

Via Business Wire

Follow-Up Data From Phase 3 Trial of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age

November 22, 2021

From Pfizer Inc.

Via Business Wire

Pfizer and BioNTech Receive Expanded U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster to Include Individuals 18 and Older

November 19, 2021

From Pfizer Inc.

Via Business Wire

Pfizer’s XELJANZ® (tofacitinib) Receives Marketing Authorization in the European Union for the Treatment of Active Ankylosing Spondylitis

November 18, 2021

From Pfizer Inc.

Via Business Wire

Pfizer to Provide U.S. Government with 10 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19

November 18, 2021

From Pfizer Inc.

Via Business Wire

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.